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ABSTRACT
We investigated the microtubule-destabilizing, vascular-targeting, anti-tumor 
and anti-metastatic activities of a new series of chalcones, whose prototype compound 
is (E)-3-(3’’-amino-4’’-methoxyphenyl)-1-(5’-methoxy-3’,4’-methylendioxyphenyl)-
2-methylprop-2-en-1-one (TUB091). X-ray crystallography showed that these 
chalcones bind to the colchicine site of tubulin and therefore prevent the curved-to-
straight structural transition of tubulin, which is required for microtubule formation. 
Accordingly, TUB091 inhibited cancer and endothelial cell growth, induced G2/M 
phase arrest and apoptosis at 1-10 nM. In addition, TUB091 displayed vascular 
disrupting effects in vitro and in the chicken chorioallantoic membrane (CAM) assay 
at low nanomolar concentrations. A water-soluble L-Lys-L-Pro derivative of TUB091 
(i.e. TUB099) showed potent antitumor activity in melanoma and breast cancer 
xenograft models by causing rapid intratumoral vascular shutdown and massive 
tumor necrosis. TUB099 also displayed anti-metastatic activity similar to that of 
combretastatin A4-phosphate. Our data indicate that this novel class of chalcones 
represents interesting lead molecules for the design of vascular disrupting agents 
(VDAs). Moreover, we provide evidence that our prodrug approach may be valuable 
for the development of anti-cancer drugs.
INTRODUCTION 
Cancer is a leading cause of death worldwide and 
its occurrence is expected to double in the following 
decades [1]. Resistance and lack of efficacy associated 
with current antineoplastic treatments demand the design 
of novel anticancer drugs [2]. Vascular Disrupting Agents 
(VDAs) constitute an innovative approach in anticancer 
therapy due to their specific mechanism of action, which 
is complementary to other existing therapies [3–5]. VDAs 
act directly and selectively at the tumor endothelium 
inducing detrimental morphological and functional 
changes. Consequently, blood flow inside the tumor is 
quickly and dramatically decreased resulting in massive 
necrosis due to the hypoxic conditions [6]. The selectivity 
of VDAs for tumor endothelium versus physiological 
vessels lies in the crucial differences between these 
vessels [4, 6]. Tumor vessels are characterized by a higher 
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proliferation rate and the lack of pericytes and a proper 
basement membrane, which makes them more fragile and 
tortuous than physiological vessels [6, 7]. Overall, this 
results in increased vascular permeability and a higher 
resistance to blood flow, making the tumor vasculature 
more sensitive to any variation in perfusion pressure [8, 9]. 
The best studied VDAs are microtubule-destabilizing 
agents that bind the αβ-tubulin dimer at the colchicine-
binding site. The most representative compounds are 
combretastatin A4 (CA-4, 1, Figure 1) and its prodrugs 
(CA-4 phosphate (2) or the serine derivative AVE-8062 
(3)) [10, 11]. In general, colchicine-site binders, when 
affecting tumor endothelial cells, block tubulin assembly 
into microtubules, which in turn induces a large cascade 
of events, such as actin stress fiber contraction and the 
subsequent activation of Rho kinases. Consequently, 
endothelial cells round up and lose their connectivity, 
leading to vascular collapse, tumor hypoxia and finally 
hemorrhagic tumor necrosis [12]. In addition, colchicine-
site binders are also able to behave as antimitotic agents 
[13]. This antimitotic effect is closely related to the 
importance of the microtubule cytoskeleton in the 
formation of the mitotic spindle during cell division [14]. 
As a consequence, several colchicine-site binders are 
currently being evaluated clinically in different combination 
regimens for the treatment of a variety of solid tumors [15].
Besides colchicine (4, Figure 1) and CA-4, 
natural products continue to be a source of microtubule-
destabilizing agents binding at the colchicine-site. We have 
centered our attention at those compounds that include a 
dioxolane group at ring A, such as combretastatin A2 [16], 
polygamain [17] or cornigerin [13]. Another interesting 
group of natural product-inspired compounds binding at 
the colchicine-site are chalcones, such as MDL-27048, 
a synthetic chalcone with significant antitumor effects in 
vitro and in vivo [18]. Other chalcones have been designed 
and synthesized with the purpose to enhance the chemical 
stability of CA-4 [11, 19]. 
Here, we synthesized new colchicine-site binders 
with a chalcone scaffold, along with a dioxolane motif 
at ring A, according to its abundant presence in natural 
colchicine-site ligands. X-ray crystallography was 
performed to gain detailed insight into the binding mode 
of this family of chalcones. The anti-proliferative and anti-
vascular properties of the compounds were determined 
and a prodrug strategy was applied in order to improve the 
water solubility of the most active compound (TUB091). 
This prodrug (TUB099) was shown to possess potent anti-
tumor and vascular-disrupting activities in primary tumor 
models and proved as potent as the reference compound 
CA-4P in inhibiting spontaneous metastasis induced by 
human breast cancer MDA-MB-231 cells. 
RESULTS
Synthesis of the chalcones
The synthesis of the chalcones involved an aldol 
condensation between a phenone fused to a dioxolane 
ring (A ring) and the corresponding benzaldehyde (ring 
B). First, we envisioned the synthesis of the unsubstituted 
chalcones at the α position of the α,β-unsaturated ketone 
(Supplementary Scheme 1). This resulted in chalcones 5–9 
(Figure 1) of which 5 and 9 with a hydroxyl or an amine 
group at position 3 of ring B, respectively, showed the best 
growth-inhibitory activity (Table 1, see further). Based on 
these data the second series of chalcones (Supplementary 
Scheme 1), incorporating a methyl group at the α position 
Figure 1: Structural formulae of reference compounds and newly synthesized chalcones.
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of the α,β-unsaturated ketone, contained only those 
compounds whose B-ring had the same substitution as 
5 and 9, thus providing compounds 10 (TUB092) and 
11 (TUB091) (Figure 1). 
Growth-inhibitory activity of the chalcones
The synthesized compounds were first evaluated for 
their growth-inhibitory activity in cancer and endothelial 
cell lines (Table 1). As reference compounds CA-4P (2) 
and colchicine (4) were included. Among unsubstituted 
chalcones at the α-position (5–9), compounds 5 and 
9, with a 3-hydroxy or 3-amine group at ring B, 
respectively, showed 50% inhibitory values (IC
50
) in 
the sub-micromolar range. The introduction of a methyl 
group at the α-position of the double bond (compounds 
10 and 11) significantly improved the growth-inhibitory 
activity. Importantly, the aminochalcone 11 (TUB091), 
with IC
50
 values between 1 and 4 nM, proved to be even 
more active than the reference compounds in all cell 
lines tested (Table 1). CA-4P as well as TUB091 also 
inhibited the growth of normal fibroblasts and peripheral 
blood mononuclear cells (PBMC) in the nanomolar range 
(Supplementary Table 1). However, it should be noted 
that, whereas the compounds were toxic at micromolar 
concentrations in tumor and endothelial cells (see further), 
they were not toxic up to 100 µM in PBMCs as evidenced 
by the fact that a slight growth of these cells was still 
observed at 100 µM of compound.
Chalcones bind to the colchicine-site of tubulin
Using impedance-based monitoring of cell growth, 
we found a time- and dose-dependent anti-mitotic 
signature in MDA-MB-231 breast cancer cells treated with 
TUB091. At concentrations higher than 5 nM, TUB091 
caused a rapid and continuous decrease in cell index, 
indicative of reduced cell adhesion and/or toxicity.  Using 
lower concentrations of TUB091, a decrease in cell index 
during the first 14 h and subsequent recovery during the 
next 24–48 h was observed, typical for tubulin-targeting 
agents [20] (Figure 2A). Accordingly, staining of the 
microtubules in MDA-MB-231 cells after 15 h treatment 
with TUB091 resulted in the appearance of aberrant 
spindles. At 10 and 5 nM of TUB091, highly irregular 
and multipolar spindles were noticed, leading to a high 
number of cells in (pro)metaphase incapable of proceeding 
to telophase (Figure 2B), while at 2.5 nM the majority of 
cells underwent proper cell division. 
The affinity of the compounds for bovine αβ-tubulin 
was studied by competition experiments with R-PT, 
whose binding to tubulin is characterized by fluorescence 
emission (Ka of 3.2 × 10
6 M−1) [21, 22]. The binding 
constant obtained for compound 10 by R-PT displacement 
was (1.3 ± 0.2) × 107 M−1, similar to the reported value for 
colchicine (1.2 × 107 M−1 at 37°C). Since the binding of 
TUB091 to tubulin resulted in a change of the fluorescence 
emission with the same excitation wavelength of R-PT, the 
binding constant of TUB091 to tubulin was determined by 
Table 1: Growth-inhibitory activity of reference compounds and newly synthesized chalcones
Endothelial Cells Tumor Cells
Compound
IC50 (µM) IC50 (µM)
HMEC-1 BAEC B16-F10.luc2 CEM HeLa
CA-4P (2) 0.0029 ± 0.0001 0.0039 ± 0.0002 0.0032 ± 0.0002 0.011 ± 0.001 0.013 ± 0.001
Colchicine (4) 0.0038 ± 0.0011 0.0069 ± 0.0008 0.021 ± 0.002 0.013 ± 0.001 0.0087 ± 0.0003
5 0.86 ± 0.90 0.040 ± 0.009 0.25 ± 0.18 0.67 ± 0.67 0.35 ± 0.26
6 1.6 ± 0.0 1.9 ± 0.3 7.8 ± 3.7 23 ± 0 5.8 ± 5.0
7 5.4 ± 0.7 4.3 ± 1.5 8.7 ± 1.6 28 ± 8 16 ± 2
8 2.1 ± 0.1 2.9 ± 2.5 12 ± 4 10 ± 0 7.2 ± 0.1
9 0.015 ± 0.007 0.0095 ± 0.0078 0.039 ± 0.023 0.080 ± 0.000 0.22 ± 0.09
TUB092 (10) 0.013 ± 0.002 0.0036 ± 0.0003 0.012 ± 0.001 0.0027 ± 0.0012 0.013 ± 0.004
TUB091 (11) 0.0023 ± 0.0005 0.0029 ± 0.0005 0.0031 ± 0.0001 0.0010 ± 0.0007 0.0039 ± 0.0033
Growth-inhibitory activity is presented as IC
50
, i.e. concentration that reduces cell growth by 50%. HMEC-1: human 
microvascular endothelial cell line-1; BAEC: bovine aortic endothelial cells; B16-F10.luc2: mouse melanoma cells expressing 
firefly luciferase 2; Cem: human lymphocytic leukemia cells; HeLa, human cervical carcinoma cells. Data are mean ± SD.
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Figure 2: Tubulin-binding activity of chalcones. (A) Growth curve of MDA-MB-231 cells in the presence of different concentrations 
of TUB091. The graph presents the normalized cell index (based on real-time impedance measurements) from 18 to 46 h after cell seeding. 
Compound was added 20 h after cell seeding (vertical line). Fast reduction in cell index with recovery of surviving cells after 14 h treatment 
(as seen at 5 nM) is specific for tubulin-binding compounds. (B) MDA-MB-231 cells were treated for 15 h with different concentrations of 
TUB091, fixed and stained with anti-β-tubulin antibody (green) to visualize the microtubules and Hoechst for DNA (blue). Cell cycle phase 
and spindle organization were investigated in individual cells (minimum 100 per condition) and quantified based on spindle morphology.
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displacement of the fluorescence of this compound by 10. 
TUB091 showed a Ka of (1.1 ± 0.1) × 10
7 M–1 similar to 
that of 10 and colchicine.
To gain detailed insights into the binding of 
these chalcones to tubulin [23], we soaked compound 
10 (TUB092, Figure 3A) into crystals of a protein complex 
composed of two αβ-tubulin (T2), the stathmin-like protein 
RB3 (R) and tubulin tyrosine ligase (TTL) [24, 25], and 
determined the crystal structure of the liganded TUB092 
(T2R-TTL-TUB092) at 2.4 Å resolution (Supplementary 
Table 2). The overall structure of tubulin in the T2R-TTL-
TUB092 complex superimposes with low rmsd of 0.236 
Å (776 Cα atoms) onto the one obtained in the absence 
of the ligand (PDB-ID 4I55) [24, 25]. The binding site 
is formed by residues of strands S8 and S9, loop T7 and 
helices H7 and H8 of β-tubulin and of loop T5 of α-tubulin 
(Figure 3B). 
The 1,3-benzodioxole ring (ring A) of TUB092 
points into the hydrophobic pocket formed by the side 
chains of β-tubulin residues Cys241, Leu242, Leu248, 
Ala250, Leu255, Met259, Ala316, Ile318 Lys352, Ala354 
and Ile378  and forms a water-mediated hydrogen bond to 
the backbone carbonyl and amide of Gly237 and Cys241, 
respectively (Figure 3C, 3D). The linker carbonyl of 
TUB092 is in hydrogen-bond distance to the backbone 
amide of Asp251. The hydroxyl and methoxy-groups at 
ring B form one direct and two water-mediated hydrogen 
bonds to the backbone carbonyls of Thr179 and Asn349, 
respectively. Moreover, both the 1,3-benzodioxole and the 
2-methoxyphenol moieties are stacked between the side 
chains of Cys241 and Leu255, and between Asn258 and 
Lys352, respectively.
When the beta chains of the tubulin-colchicine 
and the tubulin-TUB092 structures were superimposed 
(Figure 3E), both the 2-methoxyphenol and the linker 
moieties of TUB092 overlay well with the C-ring and 
parts of the B and A rings of colchicine. Moreover, two 
methoxy- and the hydroxyl-groups of TUB092 occupy the 
same positions as the corresponding groups in colchicine. 
The simpler scaffold of TUB092 allows the T5-loop 
residue Thr179 of α-tubulin to flip in and occupy a space 
that is occupied by two water molecules in the tubulin-
colchicine complex structure (Figure 3F). 
TUB091 induces apoptosis in MDA-MB-231 
human breast cancer cells
Tubulin staining of TUB091-treated MDA-
MB-231 cell cultures (Figure 2B) suggested that the 
compound causes mitotic arrest. Using flow cytometry, 
an accumulation of cells in G2/M phase was observed 
after 24 h treatment with 10 nM TUB091 (Figure 4A). 
More strikingly, the compound caused a dose-dependent 
increase in sub G1 cells, exhibiting a sub-diploid DNA 
content characteristic of apoptotic cells (45% ± 9 and 
19% ± 8 at 10 and 1 nM of TUB091, respectively). 
Induction of apoptosis was confirmed by measuring (i) the 
translocation of phosphatidylserine from the cytoplasmic 
to the extracellular side of the plasma membrane 
(Supplementary Figure 1) and (ii) the activation of 
caspase-3 by TUB091 (Figure 4B). 
TUB091 displays anti-vascular effects in vitro 
and in the CAM assay
Vascular-disrupting agents not only affect tumor 
but also endothelial cells. Indeed TUB091, colchicine 
and CA-4P dose-dependently inhibited the proliferation 
of macrovascular HUVEC and microvascular HMEC-
1 cells.  Whereas the compounds showed a comparable 
inhibitory activity in HMEC-1 cells, TUB091 proved 
about 10-fold more cytostatic than CA-4P and 100-fold 
more active than colchicine in HUVEC cells (Figure 5A). 
TUB091 (≥ 10 nM) also induced the accumulation of 
HMEC-1 cells in G2/M phase of the cell cycle (Figure 5B) 
and induced apoptosis, even at 1 nM (Figure 5B, 5C). In 
addition, TUB091 and CA-4P prevented the closure of a 
wound created in a confluent monolayer of HMEC-1 cells 
(Figure 5D).
As shown in Figure 6A, both CA-4P and TUB091 
dose-dependently abrogated the integrity of a pre-
formed vascular network of endothelial cells. TUB091 
also elicited anti-angiogenic and vascular-disrupting 
effects in vivo. Using the CAM gelatin sponge assay, the 
number of newly formed microvessels directed towards 
the sponge containing 3 nmol of TUB091 or CA-4P 
was reduced by more than 50% compared with DMSO-
containing sponges (Figure 6B). Histological examination 
of the CAMs showed a complete disappearance of the 
intermediate mesenchyme without any cellular and 
vascular components in the TUB091-treated CAMs, as 
compared to control (Figure 6C). Using larger plastic 
discs that contain the dried compound, both neovessel 
formation (angiogenesis) as well as vascular-disrupting 
activity can be investigated at the CAM area under the 
disc. A dose-dependent effect on both processes could be 
observed. Indeed, at 3 nmol, TUB091 completely blocked 
the formation of new blood vessels in nearly all CAMs 
tested and also caused damage and bleeding to immature, 
already existing vessels (Figure 6D). At 1 nmol/ disc, 
angiogenesis was inhibited, but larger vessels were not 
affected (Figure 6D). 
Prodrug synthesis
All these data point to a vascular-disrupting and anti-
angiogenic effect of TUB091 accompanied by induction of 
tumor cell apoptosis. However, its low aqueous solubility 
precluded in vivo evaluation. Therefore, we synthesized 
prodrugs of TUB091 by conjugation with L-Ser as in 
AVE-8062 (3) or with an L-Lys-L-Pro dipeptide (12 and 
13, Supplementary Methods). The latter was based on our 
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previous results of solubility improvement of antiviral 
drugs by coupling to di- or oligopeptides and subsequent 
release by the endogenous enzyme dipeptidyl peptidase 
IV (DPP-IV/CD26) [26]. 
The L-Lys-L-Pro derivative 13 (TUB099, Figure 
7A) was ~2000-fold more soluble than the parent 
drug (Figure 7B) and nearly as effective as TUB091 in 
inhibiting tumor and endothelial cell proliferation (Figure 
7C). Incubation of TUB099 in human serum or murine 
liver extract showed an efficient release of TUB091 
(Figure 7D). Biological assays further demonstrated that 
TUB099 possesses vascular-disrupting activity in vitro 
(Figure 7E) and induces G2/M phase arrest and apoptosis 
in endothelial and tumor cells (not shown).
Figure 3: X-ray analysis of the chalcone-tubulin complex. (A) Chemical structure of TUB092. (B) Overall view of the complex 
formed between αβ-tubulin and TUB092. α- and β-tubulin are in dark and light grey, respectively. (C, D). Close-up views of the interaction 
network observed between TUB092 (green) and tubulin (gray). Interacting residues of tubulin are shown in stick representation and are 
labeled. Oxygen and nitrogen atoms are colored red and blue, respectively; carbon atoms are in green (TUB092) or gray (tubulin). Hydrogen 
bonds are depicted as black broken lines. Secondary structure elements of tubulin are labeled in blue. (D) 90° rotation of C.  (E-F) Comparison 
of TUB092 and colchicine tubulin-binding modes. (E) Superimposition of the tubulin–TUB092 (dark gray ribbons) and tubulin–colchicine 
(PDB ID 4O2B, light gray ribbons) structures. TUB092 and colchicine are in green and violet-purple stick representation, respectively. 
Water molecules are displayed as red (TUB092 structure) and grey (colchicine structure) spheres, respectively. (F) Superimposition of the 
“curved” (tubulin–TUB092; light gray ribbons) and “straight” (PDB ID 1JFF; light blue ribbons) tubulin conformational states. TUB092 is 
shown in green sphere representation. Arrows highlight regions of steric clashes between straight tubulin and TUB092.
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TUB099 inhibits primary tumor growth and 
spontaneous metastasis in mice
To determine the in vivo antitumor activity of 
TUB099, melanoma and breast cancer models were 
used [27]. First, B16-F10.luc2 melanoma cells were 
injected subcutaneously (s.c.) in SCID mice. TUB099 
was injected intratumorally (i.t.) at 10 mg/kg for 
5 consecutive days starting at day 3, when small tumors 
were macroscopically visible. Tumor growth was 
measured by in vivo imaging until day 10, when TUB099-
treated tumors were no longer visible (Figure 8A). By 
day 17, TUB099 tumors had slightly regrown but were 
significantly smaller than control tumors (p < 0.001, 
Figure 8B). Only a slight, non-significant, decrease in 
body weight was noted (Supplementary Figure 2). Thus, 
in an early stage of tumor development, TUB099 exerts a 
potent anti-tumor effect when administered i.t.
Next, MDA-MB-231/4mRL.luc2 human breast 
cancer cells were injected into the mammary fad pad 
of SCID mice and the compounds (TUB099 or CA-4P) 
were administered i.t. at 15 mg/kg either once at day 
12, or for 4 consecutive days (day 12 till 15). Whereas 
control tumors continued to grow, a dramatic decrease in 
luminescent signal was noted in the TUB099 group within 
2 days after start of treatment (Figure 8C). TUB099 
proved also significantly more active than the reference 
compound CA-4P. However, caliper measurement of 
tumor size did not reveal a difference between control 
and treated groups (not shown). Since light emission by 
firefly luciferase requires oxygen and ATP, which are 
only present in living cells, our data indicate that, already 
within 48 h after start of treatment, TUB099-treated tumor 
cells were dead and/or lacked oxygen, effects that are 
typically seen with VDAs.
At day 16 after cell inoculation, primary tumors were 
removed and all mice were left untreated. Three weeks 
later, lung and/or lymph node metastases were present 
in 90% of control mice of the 4-day treatment group. In 
contrast, only 40% of CA-4P-treated mice developed 
metastases, and metastases were completely undetectable 
(based on luminescence measurement) in TUB099-treated 
mice (Figure 8D). Interestingly, among the 1-day treatment 
groups, metastases development was less evident.
Figure 4: TUB091 induces G2/M phase arrest and apoptosis in human breast cancer MDA-MB-231 cells. (A) Flow 
cytometric analysis of cell cycle distribution of MDA-MB-231 cells that were treated for 24 h with different concentrations of TUB091. 
The experiment was repeated 3 times with similar results. Results from 1 experiment are shown. (B) Caspase-3 activity in MDA-MB-231 
cells. Different concentrations of compound and 2 µM of the caspase-3 substrate DEVD-NucView488 were added to MDA-MB-231 cells. 
At indicated time-points, the cells were incubated with 2 µg/ml Hoechst 33342 to stain the nucleus, and imaged. Data are the result of 
3 experiments performed in duplicate and are expressed as mean ± SD. *p < 0.05 compared with control.
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TUB099 causes rapid vascular shutdown in 
MDA-MB-231 orthotopic breast tumors
Next, mice were treated systemically (i.p.) with one 
dose (30 or 15 mg/kg) of TUB099 or CA-4P on day 14 
after cell injection. A massive decline in luminescent signal 
was noted as soon as 2 h after treatment (Figure 9A), 
in agreement with the rapid vascular shutdown and 
consequently reduced perfusion induced by VDAs. This 
effect was still evident 24 and 48 h after treatment (i.e. 
day 15 and 16 respectively), in particular in the 30 mg/kg 
groups (Figure 9B). Again, when the primary tumors were 
removed and processed for histology, no difference was 
observed in tumor size at day 16 (Figure 9B). 
H&E staining indicated necrosis in the center of 
TUB099- and CA-4P-treated tumors, leaving a viable 
rim, whereas control tumors were entirely viable. In 
addition, while control tumors were highly vascularized 
Figure 5: Effects of TUB091 on endothelial cell functions in vitro. (A) Endothelial cell proliferation. HUVEC and HMEC-1 cells 
were seeded at 20,000 cells/cm2. After 24 h, compounds were added. The cells were allowed to grow for an additional 3 days, trypsinized 
and counted. Mean of 3 independent experiments with similar results is shown. (B) Flow cytometric analysis of cell cycle distribution 
of HMEC-1 cells that were treated for 24 h with different concentrations of TUB091. The experiment was repeated 3 times with similar 
results. Results from 1 experiment are shown. (C) Caspase-3 activity in HUVECs. Different concentrations of TUB091 or CA-4P and 2 µM 
of the caspase-3 substrate DEVD-NucView488 were added to HUVECs. At 24 h, the cells were incubated with 2 µg/ml Hoechst 33342 to 
stain the nucleus, and imaged. (D) Endothelial cell migration. Wounds were created in confluent HMEC-1 monolayers. Then, cells were 
incubated in fresh medium in the presence of the test compounds and 1 µg/ml of mitomycine C to inhibit cell proliferation. After 18 h, 
the wounds were photographed and wound repair was quantified by computerized analysis. (C, D) Data are the result of 3 experiments 
performed in duplicate and are expressed as mean ± SD. *p < 0.05 compared with control. 
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Figure 6: Anti-angiogenic and VDA activity of TUB091. (A) Disruption of the vascular network. HMEC-1 cells were cultured on 
matrigel for 3 h to allow the formation of tube-like structures. Then different concentrations of compounds were added. After 90 min, tube 
formation was quantified. Data are the result of 3 experiments performed in duplicate and are expressed as mean ± SD. *p < 0.05 compared 
with control. (B–C) Gelatin sponge CAM assay. Sponges containing 3 nmol of CA-4P or TUB091 were added onto the CAM. (B) Newly 
formed microvessels directed at the sponges were counted 4 days later (lower panel). Hundred eggs were used per condition. Data are 
expressed as mean ± SD. *p < 0.05 compared with control. Macroscopic pictures of the CAM are shown (upper panel) (C) Histological 
examination demonstrates a complete disappearance of the intermediate mesenchyme without any cellular and vascular components in 
the TUB091-treated CAMs, as compared to control. CH: chorion; M: mesenchyme, A: allantois. (D) Plastic discs containing the dried 
compound were added onto the CAM. Graph shows the percentage of CAMs with complete inhibition of blood vessel formation 2 days 
later. Data are the result of 2 independent experiments using 8 eggs per condition. *p < 0.05 compared with control.
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Figure 7: Biological evaluation of TUB091 prodrugs. (A) Structure of TUB099, the L-lysyl-L-prolyl derivative of TUB091. 
(B) Aqueous solubility of TUB091 and its prodrugs in PBS. (C) Growth-inhibitory activity is presented as IC
50
, i.e. concentration that 
reduces cell growth by 50%. HMEC-1: human microvascular endothelial cell line-1; BAEC: bovine aortic endothelial cells; Cem: human 
lymphocytic leukemia cells; HeLa, human cervical carcinoma cells. Data are mean ± SD. (D) Release of parent compound (TUB091) 
in human serum and murine liver extract. TUB099 (100 µM) was incubated for 60 and 180 min at 37°C in human serum or mouse liver 
extract. Aliquots were quantified by HPLC with detection at 305 nm. (E) Vascular-disrupting activity of TUB099. HMEC-1 cells were 
cultured on matrigel for 3 h to allow the formation of tube-like structures. Then different concentrations of TUB099 were added. After 90 
min, tube formation was quantified. Data are the result of 3 experiments performed in duplicate and are expressed as mean ± SD. *p < 0.05 
compared with control. 
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Figure 8: Intratumoral (i.t.) TUB099 impairs primary tumor growth and metastasis. (A, B) Effect of TUB099 on 
subcutaneous growth of melanoma. Thirty thousand B16.F10.luc2 cells were injected subcutaneously in SCID mice. Intratumoral (i.t.) 
treatment with TUB099 (10 mg/kg; full line) or vehicle (dashed line) was started 3 days after cell injection and continued for 5 consecutive 
days (horizontal line in A). The mice were imaged (A) at regular time intervals. Each line in A represents one single mouse. Representative 
pictures of bioluminescence in the tumors of control and TUB099-treated mice at day 10 are shown. (B) Tumor weight at day 17 after cell 
inoculation, i.e. 10 days after treatment was terminated. Data are mean ± SEM, n = 5. *p < 0.05. (C, D) Effect of TUB099 on primary tumor 
growth and metastasis of MDA-MB-231/4mRL.luc2 human breast cancer cells. 4mRL.luc2 cells (106) were injected in the mammary fat 
pad of SCID mice. PBS, TUB099 or CA-4P was administered i.t. at day 12 only (1×) or from day 12 till day 15 (4×). (C) The mice were 
imaged at regular time intervals. Data are mean ± SEM of luciferase measurements, n = 5. At day 16, a significant reduction in luminescent 
signal is visible in the CA-4P- but particularly in the TUB099-treated tumors. (D) Lung and/or lymph node metastasis 19 days after removal 
of the primary tumor (i.e. 35 days after cell inoculation). Experiments were performed twice with similar results. Results of one experiment 
are shown. 
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Figure 9: Vascular disrupting activity of systemic (i.p.) TUB099 treatment. (A–C) MDA-MB-231/4mRL.luc2 cells (106) were 
injected in the mammary fat pad of SCID mice. PBS, TUB099 or CA-4P (15 or 30 mg/kg) was administered once, intraperitoneally, at day 
14. (A) Luminescence in the tumor before (left) and 2 h after administration (right) of compound. (B) The mice were imaged at regular 
time intervals. Data are mean ± SEM, n = 5.No difference in primary tumor size was observed at day 16, when the tumors were resected 
and processed for histological evaluation (inset). (C) Total tumor sections were stained with H&E or were double immunostained with 
anti-CD31 (red) and anti-Ki67 (green) antibodies, followed by nuclear counterstaining with Hoechst (blue). Asterisks indicate necrotic 
tumor center. Higher magnification of tumor center (bottom panel). Arrow indicates viable tumor rim. Scale bar = 1 mm. Two independent 
experiments yielded comparable data.
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and showed massive staining of the proliferation 
marker Ki67 (Figure 9C), tumors obtained from CA-4P 
and TUB099-treated mice showed very little staining 
for Ki67, and no blood vessels in the tumor center 
(Figure 9C).
Again primary tumors were removed at day 16. By 
day 21 after tumor resection, 45% of the control mice were 
metastasized. CA-4P showed an anti-metastatic activity 
at 30 mg/kg (13% of mice with metastasis), whereas 
TUB099 proved equally effective in inhibiting metastasis 
at 15 and 30 mg/kg (20% of mice with metastasis) 
(not shown).
Together, our data indicate that TUB099 induces 
rapid intratumoral vascular collapse, leading to massive 
tumor necrosis, with a potency similar to that of the 
reference compound CA-4P. Moreover, TUB099 
effectively reduced spontaneous metastasis, occurring 
after resection of the primary tumors.
DISCUSSION
The growth of solid tumors and their metastatic 
dissemination are dependent on a functional blood 
supply. Therefore, the tumor vasculature is considered 
an attractive target for therapy [3, 28]. During the past 
decades much effort has been devoted to the development 
and clinical evaluation of anti-angiogenic drugs, which 
inhibit the formation of new blood vessels [28, 29]. 
However, these compounds have largely failed in the 
clinic because of resistance development, lack of efficacy 
and/or toxicity. A complimentary approach also targeting 
the tumor vasculature is the use of VDAs. These agents 
destroy the existing, abnormal intratumoral vasculature, 
leading to rapid vascular shutdown and extensive tumor 
necrosis [3, 5]. The largest group of VDAs contains 
microtubule-targeting agents, of which CA-4P is currently 
under investigation in phase II clinical trials for a variety 
of solid tumors [5, 30]. 
Here, we investigated the tubulin-binding, vascular-
targeting, anti-tumor and anti-metastatic activities of a new 
series of chalcone derivatives. The best compound of this 
series, TUB091, inhibited the proliferation of endothelial 
and tumor cell lines with 50% inhibitory concentrations 
of 1–4 nM, which is slightly better than the reference 
compounds colchicine and CA-4P. 
Using X-ray crystallography we showed that the 
chalcones bind to tubulin at the colchicine-site. While 
free tubulin dimers adopt a characteristic “curved” 
conformation in solution [31, 32], tubulin dimers that 
are incorporated in microtubules undergo a curved-to-
straight structural transition [33, 34]. This process is 
necessary for microtubule formation and is associated with 
a rearrangement of several secondary structural elements 
thereby occluding the colchicine-site [23, 35, 36]. The 
superposition of the modeled tubulin-TUB092 structure in 
the context of the straight conformational state of tubulin 
showed several potential clashes of TUB092 with residues 
from the helices H8 and H7, the beta strand S9 and the 
T7 loop of β-tubulin and from the T5 loop of α-tubulin. 
This observation suggests that TUB092 cannot bind to 
the colchicine-site in preformed microtubules. Thus, 
the microtubule-destabilizing activity of TUB092 likely 
consists in preventing the curved to-straight structural 
transition in tubulin by the bound ligand, as previously 
reported for other colchicine-site ligands [23, 36]. 
Together, our data demonstrate that the newly 
synthesized chalcones destabilize microtubules by binding 
to the colchicine-site of tubulin. This destabilization 
causes depolymerization of the mitotic spindles leading 
to the lack of DNA organization into a metaphase plate. 
Immunocytochemistry showed a dose-dependent increase 
in (pro)metaphase cells containing abnormal mitotic 
spindles, in the presence of TUB091. Accordingly, 
TUB091 caused an arrest of tumor and endothelial cells 
in G2/M phase and induced apoptosis in these cells at 
nanomolar concentrations. 
Furthermore, we found a potent and dose-dependent 
inhibition of other endothelial cell-specific responses. 
Indeed, TUB091 inhibited endothelial cell migration 
and angiogenesis in the CAM assay. The compound also 
caused the disruption of an existing network of endothelial 
tubes in vitro and the degradation of newly formed, 
immature vessels in the CAM assay. In contrast, the 
larger, mature vasculature was not affected by TUB091. 
Indeed, significant structural differences exist between 
immature and mature vasculature. While immature 
vessels rely on microtubules for structural support and 
are particularly sensitive to VDAs, mature vessels are 
supported by pericytes and a solid basement membrane 
and are therefore protected from disruption by VDAs [37]. 
Previously, prodrugs of combretastatins were 
developed to overcome solubility limitations that 
precluded clinical testing. Sodium phosphate salt 
derivatives of CA-4 (CA-4P) and CA-1 (CA-1P) and the 
L-serine prodrug of an amino derivative of CA-4 (AVE-
8062, rapidly advanced to clinical trials [reviewed in 
[5]). We have extensively investigated the development 
of oligopeptide prodrugs that are efficiently release in 
the presence of dipeptidyl peptidase IV (DPP-IV/CD26) 
[26]. This enzyme, abundantly found in serum, mainly 
hydrolyzes peptidic sequences containing an N-terminal 
penultimate proline. In particular, drug conjugation with 
an L-lysyl-L-prolyl dipeptide may significantly increase 
the solubility due to the basicity of the N-terminal lysine, 
while recognition by CD26 may enhance the in vivo 
release of the parent drug. Indeed, the L-lysyl-L-prolyl 
dipeptide prodrug of TUB091 (TUB099) displayed 
2000-fold improved solubility compared to TUB091 and 
efficiently released the parent drug. This prodrug inhibited 
endothelial and tumor cell proliferation, induced apoptosis 
and showed vascular-disrupting activity in cell culture. 
In addition, when administered either intratumorally 
(i.t.) or systemically (i.p.), TUB099 reduced the primary 
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growth of mouse melanoma B16.F10.luc2 and human 
breast cancer MDA-MB-231/4mRL.luc2 cells in mice. 
Whereas i.t. treatment of small tumors with TUB099 
resulted in complete regression within 4 days, no 
immediate macroscopic effect on tumor size was noted 
when larger tumors were treated with TUB099 or CA-4P. 
Interestingly, already 2 hours after compound injection, 
a prominent reduction in luminescence was observed, 
indicative of vascular shutdown and consequently reduced 
tumor cell perfusion. Accordingly, whereas PBS-treated 
tumors were highly proliferative and vascularized, as 
demonstrated by extensive Ki67 and CD31 staining, 
immunohistochemical analysis of tumors dissected 
2 days after treatment with TUB099 and CA-4P showed 
massive necrosis in the tumor center, leaving only a small 
viable rim. These effects are typically seen with vascular-
targeting agents [37]. Since these peripheral tumor cells 
are more accessible to conventional chemotherapy, 
combretastatins are mainly used to complement traditional 
anticancer treatments, including various cytostatic agents 
or radiotherapy (reviewed in [5]). 
To evaluate the effect of TUB099 on spontaneous 
metastasis, primary tumors were removed after treatment. 
Whereas some PBS-treated tumors regrew during the next 
weeks, the mice that were previously treated with either 
TUB099 or CA-4P remained tumor-free. Furthermore, 
87% of control mice developed lung and/or lymph node 
metastases within 4 weeks after tumor resection, whereas 
metastases were only visible in 40% of CA-4P treated 
animals and were completely absent in the TUB099 
group. Interestingly, much less metastases were observed 
in the control mice receiving just one i.t. injection of PBS, 
compared to the mice that received PBS for 4 consecutive 
days. These data suggest that i.t. injection may damage 
tumor architecture and the intratumoral vasculature, 
thereby facilitating the escape of tumor cells into the 
circulation and their dissemination to distant organs [39]. 
Taken together, our data indicate that this series of 
chalcones open a new horizon for the design of innovative 
VDAs, since their interaction with their molecular target 
has also been resolved and presented. Interestingly, they 
show a superior antitumor activity over the reference VDA 
CA-4P. Finally, we provide evidence that our prodrug 
approach, that so far has been mainly used to develop more 
soluble antivirals, may also be very valuable to improve 
bioavailability of highly hydrophobic anti-cancer drugs.
MATERIALS AND METHODS
Compounds
Colchicine was obtained from Calbiochem 
(Darmstadt, Germany) and CA-4P (fosbretulin) from 
Sigma-Aldrich (Diegem, Belgium). The synthesis, 
analytical and spectroscopic data of compounds 5–13 are 
shown in the Supplemental Experimental Procedures. 
Cell lines
Human umbilical vein endothelial cells (HUVEC) 
were purchased from Lonza and grown in macrovascular 
endothelial cell medium (EGM2, Lonza, Verviers, 
Belgium). The human microvascular endothelial cell line 
HMEC-1 was obtained at passage 12 from the Centers for 
Disease Control and Prevention (Atlanta, GA, USA) and 
used from passage 17 till 27. Bovine aortic endothelial 
cells (BAEC) were purchased from Lonza at passage 
3 and were used up to passage 20. Human embryonic lung 
HEL-299 fibroblasts were obtained from ATCC, used 
up to passage 10 and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA), 
supplemented with 10% fetal bovine serum (FBS, Gibco), 
0.01M Hepes (Gibco) and 1 mM sodium pyruvate (Gibco). 
Buffy coat preparations from healthy donors were obtained 
from the Blood Transfusion Center in Mechelen, Belgium. 
Peripheral blood mononuclear cells (PBMC) were isolated 
by density gradient centrifugation over Lymphoprep 
(d = 1.077 g/ml) (Nycomed, Oslo, Norway) and cultured in 
RPMI 1640 containing 10% FBS and 2 mM L-glutamine. 
Luciferase-expressing murine melanoma (B16-F10.luc2) 
and human breast carcinoma (MDA-MB-231.luc2) cells 
were obtained from Perkin Elmer (Zaventem, Belgium). 
A metastatic MDA-MB-231.luc2 cell line (231/4mRL.
luc2) was derived by serial in vivo selection of metastases 
that emerged following resection of the primary orthotopic 
tumor according to Munoz et al. [40]. Human cervical 
carcinoma (HeLa) and human T-lymphoid (CEM) cells 
were obtained from ATCC (Middlesex, UK). Cell lines 
were maintained in culture for up to 3 months and grown 
in DMEM, supplemented with 10% FBS, 0.01M Hepes 
and 1 mM sodium pyruvate. All cells were cultured in a 
humidified 5% CO2 incubator at 37°C. No authentication 
was done since the cell lines were purchased.  
Cell growth inhibition and cytotoxicity studies
BAEC, MDA-MB-231, B16.F10.luc2 and HeLa 
cells were seeded at 10,000 cells/cm2. HUVEC, HMEC-1 
and Hel cells were seeded at 20,000 cells/cm2. After 24 
h, 5-fold dilutions of the compounds were added. Three 
days (4 days for HUVEC and HMEC-1 and 6 days for 
Hel) later the cells were counted by means of a Coulter 
counter (Analis, Belgium). CEM cells were seeded at 
180,000 cells/cm2 in the presence of the compounds, 
allowed to proliferate for 96 h and counted. One day after 
isolation, PBMC were stimulated with phytohemagglutinin 
(2 µg/ml) for 48 h. Next, cells were seeded at 450,000 
cells/cm2, treated with compound and interleukin-2 (20U/
ml) for 6 days and counted.
Cytotoxicity was studied using the xCELLigence 
RTCA DP instrument (Acea Biosciences, San Diego, CA, 
USA). 100 µl of cell-free growth medium was added to the 
wells of an E-plate VIEW 16 PET (Acea Biosciences) and 
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allowed to equilibrate for 1 h for background impedance 
measurement. Next, 4,000 MDA-MB-231 cells/100 µl were 
added to the wells. After overnight incubation, 50 µl of 
compound was added. The impedance value was monitored 
every 15 min for 24 h and expressed as Cell index (CI). CI 
was normalized at the time of addition of the compound.
Immunocytochemistry
MDA-MB-231 cells were seeded overnight on poly-
L-Lysine coated 8-well Millicell slides (Millipore). Next, 
compounds were added for 15 h. Fixed and permeabilized 
cells were stained with a monoclonal anti-β-tubulin 
antibody (2 µg/ml, Sigma-Aldrich) for 2 h at RT. After 
washing, cells were incubated with goat anti-mouse 
Alexa Fluor 488 antibody (4 µg/ml; Molecular Probes, 
Invitrogen) as described [22]. Nuclei were stained with 
2 µg/ml Hoechst33342 (Sigma-Aldrich). Fluorescence 
microscopy was done using an Axiovert 200 M inverted 
microscope (Zeiss, Göttingen, Germany).
Tubulin polymerization-determination of 
binding constants
Calf brain tubulin was purified as described 
[22, 41]. (R)-(+)-ethyl 5-amino 2-methyl-1, 2-dihydro-3-
phenylpyrido[3, 4-b]pyrazin-7-yl carbamate (R-PT) was a 
kind gift of Prof. Rener, Birmingham, Alabama [42]. 
The binding constant of TUB092 to tubulin was 
determined by competition with R-PT [21, 22]. The 
binding constant of TUB091 to tubulin was determined 
by competition with TUB092. The fluorescence emission 
spectra (excitation at 374 nm) of 0.4 µM Tubulin and 
0.4 µM TUB091, 0.1 mM GTP pH 7.0, were measured in 
the presence of growing concentrations of TUB092 using 
a Jobin-Ybon SPEX Fluoromax-2 (HORIBA, Ltd. Kyoto, 
Japan). The decrease of the fluorescence intensity of 
TUB091 at the maximum upon incubation with TUB092 
was used to determine the binding constant using Equigra 
V5.0 as described [43]. 
Crystallization, data collection, and structure 
solution
Crystals of T2R-TTL were generated as described 
[24, 25, 36]. Suitable T2R-TTL crystals were exchanged 
into reservoir solutions containing 2 mM TUB092 and 
soaked overnight. Soaked crystals were flash cooled 
in liquid nitrogen following a brief transfer into cryo 
solution containing 20% glycerol. T2R-TTL TUB-92 data 
were collected at beamline X06SA at the Swiss Light 
Source (Paul Scherrer Institut, Villigen, Switzerland). 
Images were indexed and processed using XDS [44]. 
Structure solution using the difference Fourier method 
and refinement were performed using PHENIX [45]. 
Model building was carried out iteratively using the Coot 
software [46]. Data collection and refinement statistics are 
given in Supplementary Table 1. Coordinates of the T2R-
TTL-TUB092 complex have been deposited at the Protein 
Data Bank (PDB) under accession number 5JVD. 
Structural analysis and figure preparation
Molecular graphics and analyses were performed 
with PyMol (The PyMOL Molecular Graphics System, 
Version 1.5.0.5. Schrödinger, LLC). Chains in the 
T2R-TTL complex were defined as follows: chain A, 
α-tubulin-1; chain B, β-tubulin-1; chain C, α-tubulin-2; 
chain D, β-tubulin-2; chain E, RB3; chain F, TTL.
Cell cycle analysis
MDA-MB-231 or HMEC-1 cells were seeded 
overnight at 15,000 cells/cm2 or 20,000 cells/cm2, 
respectively. Next, compounds were added for 24 h. 
The cells were stained with propidium iodide using the 
CycleTEST PLUS DNA Reagent Kit (BD Biosciences, 
San Jose, CA) [22] and their DNA content assessed using 
a FACSCalibur flow cytometer (BD Biosciences). 
Fluorescence detection of caspase-3 activity in 
live cells
MDA-MB-231 cells or HUVECs were seeded at 
40,000 cells/cm² or 15,000 cells/cm² respectively. After 
24 h, cells were incubated in Fluorobrite (Gibco)-containing 
growth medium or HUVEC growth medium, with the 
compound and 2 µM of the caspase-3 substrate DEVD-
NucView488 (Biotium, Hayward, CA). At indicated time-
points the DNA was stained with Hoechst33342 and the 
cells were imaged by fluorescence microscopy. 
Wound healing (scratch assay)
Wounds were created in confluent HMEC-1 
monolayers with a 1.0-mm wide micropipette tip. Then, 
cells were incubated in fresh medium containing the 
compounds and 1 µg/ml of mitomycine C. After 18 h, 
wounds were photographed and wound repair was 
quantified by computerized analysis.
Tube destruction
Wells of a 96-well plate were coated with 70 µl 
matrigel (10 mg/ml, BD Biosciences, Heidelberg, 
Germany) at 4°C. After gelatinization at 37°C during 
30 min, HMEC-1 cells were seeded at 60,000 cells/well on 
top of the matrigel. After 3 h of incubation at 37°C, when 
tube-like structures were detectable, compounds were 
added. Ninety minutes later, tube destruction was evaluated 
by giving a score from 0 to 3 (3: intact tubular network; 2: 
missing connections and/or dead ends; 1: many separate, 
small tubes that are not connected; 0: no tubes) [22]. 
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Chorioallantoic membrane (CAM) assay
The in vivo CAM angiogenesis model was 
performed as described [47, 48]. At day 9 of fertilization, 
sterile plastic discs containing either vehicle or the 
compound and cortisone acetate (100 µg/disc, Sigma, 
St. Louis, MO) were placed on the CAM. Next, the eggs 
were incubated until day 11 when the area around the discs 
was cut-off and photographed. Results were analyzed by 
two-tailed paired Student’s t-test. In another series of 
experiments, gelatin sponges were used as vehicle, and 
the number of blood vessels converging towards the 
sponge were quantified, as described previously (48). For 
histological examination, the CAM was fixed in ovo in 
Bouin’s fluid, removed and processed for embedding in 
paraffin. Ten-micrometer serial sections were cut parallel 
to the surface of the CAM and observed under light 
microscope without staining.
Solubility of the compounds
An excess amount of the tested compound was 
added to 400 µL PBS (1% DMSO), shaken at RT for 
2 h and centrifuged. An aliquot of each supernatant 
was analyzed by UV (Thermo Multiskan Spectrum) by 
comparison with a five-point standard calibration curve. 
Stability of the compounds
The test compounds (100 µM) were incubated 
for 60 and 180 min at 37°C in concentrated mouse liver 
extract (50 % in PBS in a final volume of 200 µl) or human 
serum (10 % in PBS in a final volume of 300 µl). Next, 
50 µl of the reaction mixture were withdrawn and added 
to 100 µl ice-cold methanol for another 10 min. Then, 
the mixtures were centrifuged for 10 min at 10,000 rpm, 
and the supernatants evaporated in a Speedvac apparatus 
(Savant; Werchter, Belgium). The dried residue was 
resolubilized in PBS and analysed on a C18 reverse phase 
column (LiChroCard, Merck, Darmstadt, Germany) by 
HPLC (Waters, Milford, MA) using a gradient system 
of water/acetonitrille (50%). Compound detection was 
performed at 305 nm. 
Animals
Female severe combined immunodeficient (SCID) 
mice, weighing about 20 g were used. The animals were 
bred at the animal facility of the Rega Institute. All studies 
were done in compliance with the ethical guidelines for 
animal welfare of the KU Leuven (P028/2011).
Primary tumor models
Thirty thousand B16-F10-luc2 cells were injected 
subcutaneously (s.c.) in SCID mice. Intratumoral (i.t.) 
treatment with vehicle or TUB099 (10 mg/kg) was started 
3 days after cell injection and continued for 5 consecutive 
days. 
MDA.MB.231/4mRL.luc2 cells (106) were 
suspended in 50 µL of 50% matrigel/PBS and injected 
in the mammary fat pad of SCID mice. The mice were 
treated intraperitoneally (i.p.) with vehicle, TUB099 or 
CA-4P at day 14 or treated i.t. at day 12 or at day 12 till 
day 15. At day 16, primary tumors were removed and 
processed for histological examination. The growth of 
the luciferase-positive tumor cells and the appearance 
of metastases were quantified using the IVIS spectrum 
imaging system (Caliper Life Sciences, Hopkinton, MA, 
USA) [27, 49]. Before imaging, the mice were injected s.c. 
with 200 µl of luciferin (15 mg/ml in PBS). 
Immunohistochemical analysis of the tumors
IHC staining of the tumors was performed as 
described [27]. Paraffin-embedded sections were stained 
ON at 4°C with a rabbit anti-CD31 (4 µg/ml, Abcam) and 
a rat anti-Ki67 (1 µg/ml, eBioscience) antibody. After 
washing, sections were incubated for 3 h at RT with Alexa 
Fluor 568 goat anti-rabbit antibody (4 µg/ml; Molecular 
probes) and Dylight 650 conjugated goat anti-rat antibody 
(4 µg/ml; Thermofisher) and examined by fluorescence 
microscopy. 
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